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Abstract 4 
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LRRK2 as a cause of some forms of familial PD there has been substantial interest in finding chemical 6 
modulators of LRRK2 function. Most of the pathogenic mutations in LRRK2 are within the enzymatic 7 
cores of the protein; therefore many screens have focused on finding chemical modulators of this 8 
enzymatic activity. There are alternative screening approaches which could be taken to investigate 9 
compounds which modulate LRRK2 cellular functions. These screens are more often phenotypic 10 
screens. The preparation for a screen has to be rigorous and enable high throughout accurate 11 
assessment of a compounds activity. The pipeline to beginning a drug screen and some LRRK2 12 
inhibitor and phenotypic screens will be discussed. 13 
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FRET: time resolved fluorescence resonance transfer, TMRM: tetramethlyrhodamine, OTCA: L-2-18 
oxothiazolidine-4-carboxylic acid, PRDX3: Peroxiredoxin 3, UDCA: usrodeoxycholic acid 19 
Introduction 20 
Mutations in the LRRK2 gene are pathogenic causing late onset autosomal dominant PD. The LRRK2 21 
genotype is also associated with sporadic PD [1]. The exact cellular function of LRRK2 remains to be 22 
elucidated with much evidence linking LRRK2 to several cellular pathways. Most of the known 23 
pathogenic mutations in LRRK2 occur in the enzymatic domains with the most common mutation 24 
LRRK2G2019S leading to increased LRRK2 kinase activity [2, 3] and other mutations resulting in 25 
decreased GTPase activity [4-6]. How the two active domains interact and control one another is still 26 
an area of active and intense research. The penetrance of LRRK2G2019S is age dependent and varies 27 
between different ethnic populations [reviewed by 7]. The increased kinase activity of LRRK2 G2019S 28 
mutation coupled with the reduced penetrance of this mutation suggests biological rescue or 29 
protective mechanisms are present in some individuals. This has led to LRRK2 and in particular 30 
LRRK2 kinase activity being the target of intense drug screening activity over the past decade. The 31 
hope being a drug may be found which could reduce the risk of asymptomatic LRRK2G2019S carriers 32 
developing clinically manifest PD.  In addition as LRRK2 is a susceptibility factor for developing 33 
sporadic PD; could a LRRK2 targeted treatment be beneficial for a large sporadic patient group. This 34 
review will outline the drug screening process up to lead selection, in the context of LRRK2 as a 35 
target for PD therapies.  36 
Drug screening 37 
There are many stages to successfully setting up, running and completing a drug screen of small 38 
molecules using high throughput screening (HTS). HTS is the mainstay of the drug discovery process 39 
both in industry and increasingly academic laboratories. HTS requires each step to be considered 40 
carefully, tested and the appropriate decision made; with the input of scientists from several 41 
disciplines. The decision tree is often not straightforward but requires consideration of the aim and 42 
desired outcome of this screen. In general the drug screening process (using HTS) can be broken 43 
down into five sections; target choice, assay development, compound high throughput screening 44 
(HTS), lead selection and optimization; and toxicity testing. This review will focus on the stages up to 45 
lead selection.  46 
Target choice 47 
When selecting a target for HTS the major concern is disease relevance. The target may be a well 48 
described enzyme or receptor which is well characterized in a particular disease in which case the 49 
rationale for screening this specific target is high. The target could also be a relatively novel target 50 
for a disease where the knowledge of how this target links to disease pathogenesis is less clear but 51 
the novelty of resulting compounds is extremely high. Regarding LRRK2, this is a specific target which 52 
has been well described and linked to PD for several years. The focus of LRRK2 HTS has been to find 53 
novel, specific LRKK2 kinase inhibitors with large scale screens having been undertaken by several 54 
large pharmaceutical companies and academic laboratories. Several have been publically disclosed 55 
now and some are in pre-clinical development [8-27]. These screens have included several assays to 56 
interrogate LRRK2 kinase function, in addition to in silico and chemoproteomic approaches [17, 26]. 57 
In addition screening to identify modulators of the GTPase domain has been performed using in vitro 58 
and computer aided screening assays [28, 29]. LRRK2 biology also holds other opportunities for drug 59 
discovery by investigating chemical modulators of other LRRK2 cellular functions. So far this type of 60 
assay have been mainly limited in the LRRK2 field to small scale assessment of a compounds ability 61 
to rescue cell/neuron death seen in LRRK2 models [30-33] and to date does not include a large scale 62 
screen focusing on LRRK2 modulators. In addition to disease relevance, the screenability of a target 63 
is an important consideration for any target. Screenability means the ease with which a target can 64 
be screened using HTS and small molecules. For LRRK2 kinase inhibitors the screenability is very high 65 
with specific screens being designed to assess a compounds ability to inhibit specifically LRRK2 66 
kinase activity; these screens are often designed around specific phosphorylation assays using 67 
recombinant LRRK2 or LRRK2 peptide. For other chemical modulators of LRRK2 this may vary and 68 
depend on the ability to screen a particular receptor or enzyme linked to LRRK2. Many successful 69 
screens are carried out against a specific known molecular target, however in recent years there has 70 
been an increase in phenotypic or cell based HTS. This is sometimes ƌĞĨĞƌƌĞĚƚŽĂƐĂ ‘ďůĂĐŬďŽǆ ?71 
approach but is gaining favor again for complex diseases; as it is being recognized that more than 72 
one target will have to be modulated and by using phenotypic screening this can be achieved [34]. 73 
This type of phenotypic screen would be applicable to screening for modulators of other LRRK2 74 
functions within the cell and has proven to be a successful approach in other diseases [35]. 75 
Assay development and optimization 76 
The first step to assay development is deciding which type of assay, a biochemical assay or a cell 77 
based assay. Here we mean a biochemical assay to be against a specific target  ? this is the approach 78 
taken for most LRRK2 kinase inhibitor screens. For example Henderson et al, undertook a FRET based 79 
screen using tagged truncated LRRK2 protein and LRRK2 peptide as substrates, a similar strategy has 80 
been employed by others using MBP and LRRKtide phosphorylation of G2019S LRRK2 [26, 36]. 81 
Alternatively the cell-based approach can be used to assess a phenotypic read out in a whole cell 82 
where the specific target the compound is interacting with is unknown. So far there is no study using 83 
this approach specifically for LRRK2 published, however we and others have used it as an approach 84 
for PD and other neurodegenerative diseases [30, 35]. The situation often arises where both types of 85 
assay are used in the primary and then secondary screening assays; so if a cell based assay is used as 86 
a primary screen, then a biochemical assay will be used in the secondary screening phase to narrow 87 
the target identification and vice versa. Commonly used modalities for assays are using absorbance, 88 
luminescence and fluorescence assays with high content imaging becoming increasingly popular to 89 
use with the advent of more advanced high content imaging systems and the return to cell-based 90 
screens. The types of assays which are most commonly used for each type of screen are discussed in 91 
details elsewhere [37, 38]. Many of the LRRK2 kinase inhibitor screens have used a biochemical 92 
assay based upon phosphorylation by either WT, truncated or mutant LRRK2 of MBP or LRRKtide 93 
substrates and have yielded promising candidates; some of which have been taken forward into pre-94 
clinical testing [15]. One example of a biochemical assay which was developed for screening of 95 
LRRK2 kinase inhibitors was the one by Lui et al [10]. This group developed a HTS assay using full 96 
length LRRK2 purified from mouse brain. The primary screen identified compounds which modified 97 
LRRK2 kinase activity by directly interacting with the kinase domain of LRRK2 and compounds which 98 
modified kinase activity allosterically by interacting with the other domains of LRRK2. Another 99 
example of a primary screen used which has identified a very promising LRRK2 inhibitor MLi-2 100 
utilized Lanthascreen technology using a tagged truncated human mutant G2019S LRRK2 and a 101 
fluorescently labelled LRRKtide substrate [15]. 102 
Regardless of the type of assay used there are several validation criteria which should be fulfilled by 103 
the assay to ensure it is suitable for HTS. Optimizing of the screening assay for statistical robustness 104 
is a critical step in the HTS pathway. There are several considerations for a biochemical assay such as 105 
ligand concentration and incubation time which need to be optimized for each assay (many of these 106 
are discussed in details elsewhere, 37). For cell based assays the major consideration is the quality, 107 
amount and stability of the cells to be used. Common cell types used are tumor cell lines however it 108 
is becoming more common to carry out HTS using primary patient cells such as fibroblasts [30, 35] or 109 
ŝW^ ?Ɛ [38, 39]. Once established the assay is assessed for robustness and reproducibility.  dŚĞ ?110 
score is generally used for this and the accepted criteria are  ?A? ? ? ?(cell based HTS) ǁŚĞƌĞĂƐ ?A? ? ? ?111 
(biochemical screen). The difference here relates to the fact that cell based screen are inherently 112 
more variable.  113 
The LRRK2 screen optimized and used by Lui et al, referred to above; used a TR-FRET assay in which 114 
ĨŝƌƐƚƚŚĞĞŶǌǇŵĞĂŵŽƵŶƚĂŶĚ'dWĐŽŶƚĞŶƚǁĞƌĞŽƉƚŝŵŝǌĞĚ ?Ƶ^ďƐĞƋƵĞŶƚůǇƚŚĞ ?ƐĐŽƌĞǁĂƐĐĂůĐƵůĂƚĞĚ115 
on 3 separate platĞƐƌĞƐƵůƚŝŶŐŝŶĂŵĞĂŶ ?ƐĐŽƌĞŽĨ ? ? ? ?ǁŚŝĐŚŝƐĂƚĂŶĂĐĐĞƉƚĂďůĞůĞǀĞůƚŽĐŽŶƚŝŶƵĞ116 
and use the assay for HTS [10]. Lovitt et al also optimized the conditions for a screen using the 117 
phosphorylation of MBP and LRRKtide by G2019S LRRK2 [36]. These authors explored the various 118 
parameters in the assay to fully to establish the conditions used by Chen et al and Henderson et al 119 
for their LRRK2 inhibitor screens [36, 40]. Both of these screens found lead compounds which were 120 
not very selective for LRRK2, therefore they employed different approaches, Chen et al, undertook a 121 
computational screen using homology modelling and ATP binding site analysis whereas Henderson 122 
et al used kinase selectivity panel, ligand efficiency, lipophilic efficiency and CNS desirability scores.  123 
In terms of cell based phenotypic screens, we have developed a mitochondrial screen in patient 124 
fibroblasts [30]. This screen was performed in fibroblasts from patients with parkin mutations and 125 
ǁĞĐĂůĐƵůĂƚĞĚĂ ?ƐĐŽƌĞof 0.72 using a positive control of L-2-oxothiazolidine-4-carboxylic acid 126 
(OTCA) [30]. Subsequently the hits from this screen were used in fibroblasts from patients with 127 
LRRK2 G2019S and a Drosophila G2019S LRRK2 model and were shown to be effective [30, 31].  128 
Mitochondria and LRRK2 129 
As outlined above the functions of LRRK2 are numerous and depend on the state of the cell. LRRK2 is 130 
widely expressed in many tissues and cell types. Most is present in the cytosol with a proportion 131 
found in organelles such as the mitochondria, Golgi, endosomes and lysosomes. There are multiple 132 
strands of evidence indicating that LRRK2 mutations cause mitochondrial dysfunction [41-47], 133 
however how this happens is not clear. In particular our work has shown fibroblasts from patients 134 
with the LRRK2G2019S mutation have identified mitochondrial functional abnormalities including 135 
reduced mitochondrial membrane potential, a specific reduction in complexes III and IV of the 136 
respiratory chain rather than complex I which is seen in parkin mutant patient cells and this has an 137 
overall effect of reducing total cellular ATP levels [30]. Furthermore we have shown some defects 138 
are also present in fibroblasts from LRRK2G2019S ŵƵƚĂƚŝŽŶĐĂƌƌŝĞƌƐǁŚŽĚŽŶŽƚŚĂǀĞWĂƌŬŝŶƐŽŶ ?Ɛ139 
symptoms; however the reduction in mitochondrial membrane potential, complex III and IV activity 140 
and changes in mitochondrial morphology are less severe in non-manifesting LRRK2G2019S mutation 141 
carriers [41]. Several studies have proposed ways in which LRRK2 interacts with mitochondria in 142 
various cell and in vivo models. Studies by others have implicated a potential role of mitochondrial 143 
uncoupling in LRRK2 patient fibroblasts [42]. Peroxiredoxin 3 (PRDX3) a mitochondrial antioxidant 144 
protein; interacts with in a yeast 2 hybrid screen and neuroblastoma cells, this indicates reduced 145 
potential of mitochondria to scavenge reactive oxygen species may be linked to the mitochondrial 146 
dysfunction seen in LRRK2 linked PD [44]. In addition pathogenic mutations in LRRK2 increase 147 
inhibition of PDRX3 by phosphorylation thereby promoting oxidative damage to the mitochondria. 148 
Evidence is growing for an interaction between Drp1 and LRRK2. Drp1 is involved in mitochondrial 149 
morphology. Drp1 has been shown to interact and partially co-localise with LRRK2 in cortical 150 
neurons; indicating mutant LRRK2 could disrupt mitochondrial dynamics via this interaction [46, 47], 151 
this links with our own data showing the mitochondrial network is more branched in G2019S mutant 152 
LRRK2 patient fibroblasts [31]. All of this data suggests using a mitochondrial cell based HTS to 153 
identify modulators of mitochondrial function could discover useful compounds for the treatment of 154 
PD. Indeed our own work following on from the mitochondrial cell based screen first reported in 155 
parkin mutant patient fibroblasts [30] resulted in the identification of usrodeoxycholic acid (UDCA) 156 
which we have also shown to increase mitochondrial function in LRRK2G2019S mutant manifesting [30] 157 
and non-manifesting [41] patient fibroblasts. Another potential avenue to explore using phenotypic 158 
screening for LRRK2 would be furthering the work showing that treating both in vitro and in vivo 159 
models with a microtubule deacetylase inhibitor, such as trichostatin A, rescues the axonal transport 160 
defects seen in these models [32]. One of the areas which has hampered clinical development of 161 
LRRK2 modulators is no clear consensus on LRRK2 substrates; an advancement in this area was made 162 
recently when a subset of Rab GTPases were identified as key LRRK2 substrates acting both in vitro 163 
and in vivo at a conserved residue in the switch II domain [48]. In addition this group also found that 164 
pathogenic mutations in LRRK2 increase phosphorylation of Rabs which in turn decreases their 165 
affinity to regulatory proteins [48]. This exciting discovery opens new opportunities for developing 166 
new screening assays to find novel modulators of LRRK2 function. 167 
As discussed above phenotypic screens are often used as secondary screens when biochemical 168 
screens have been used as primary screens. This has been the case for several LRRK2 kinase 169 
inhibitors; PF-06447475 inhibitor has been shown to be protective in a mitochondrial dysfunction 170 
induced model (by rotenone treatment) in nerve-like cells [33]. GW5074 and indurubin-3 ?-171 
monooxime were shown to be protective in vitro in neurons overexpressing WT or G2019S LRRK2 172 
and in vivo in a mouse model of LRRK2 dopaminergic neuron toxicity [49]. Finally any treatment 173 
whether found using a biochemical or phenotypic LRRK2 screen needs to be safe to use in man; 174 
which means some target engagement should be able to be monitored in patients whilst they are 175 
taking the therapy. Studies have shown treatment of rodent models with LRRK2 inhibitors have 176 
shown dephosphorylation at S910 and S935 and treatment of peripheral mononuclear cells taken 177 
from Parkinson ?ƐƉĂƚŝĞŶƚƐǁŝƚŚW&-06447475 and GSK2578215A showed reduced phosphorylation at 178 
S910 and S935 [50]. 179 
Summary 180 
In summary LRRK2 is a well characterised target for HTS to find a disease modifying therapy for PD, 181 
using either a strategy of screening for LRRK2 kinase inhibitors or other modulators of LRRK2 182 
function; the main avenues of screening approaches discussed here are highlighted in Figure 1. 183 
There has already been an immense amount of work done in this area already however there is 184 
scope for much more. 185 
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